Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,388 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,388 Papers indexed
371 Papers AI scored
37,388 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-08-27 09:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37388 results
B
AI -
Base 73.4
Rank 73.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 22.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Base 73.4
Rank 73.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 32.0; sample size: 20.0; recency: 80.0; abstract quality: 100.0.

B
Potential Cause-and-Effect Relationship between Gut Microbiota and Childhood Neuroblastoma: A Mendelian Randomization Analysis.
PMID 38536652 Published: 2024-03-27 Ingested: 2026-08-02 12:04 AM Indian journal of pediatrics
AI -
Base 73.4
Rank 73.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 22.0; sample size: 60.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Base 73.4
Rank 73.4
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 22.0; sample size: 90.0; recency: 80.0; abstract quality: 85.0.

B
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.
PMID 40181694 Published: 2025-04-04 Ingested: 2026-08-02 12:04 AM Alimentary pharmacology & therapeutics
AI -
Base 73.38
Rank 73.38
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 74.4; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 73.36
Rank 73.36
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 34.3; sample size: 90.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Base 73.36
Rank 73.36
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 46.8; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group.
PMID 38197878 Published: 2025-03-03 Ingested: 2026-08-02 12:04 AM Clinical cancer research : an official journal of the American Association for Cancer Research
AI -
Base 73.36
Rank 73.36
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 71.8; sample size: 80.0; recency: 90.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 73.4/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 16.8; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 372 of 3116
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic